Multiple Ophthalmic Companies Secure Hundreds of Millions in Funding to Accelerate Core Pipeline Clinical Trials

　　【Pharmaceutical Network Industry Dynamics】Driven by multiple factors such as changes in population structure, the widespread use of electronic devices, increasing public health demands, and continuous technological innovation, the ophthalmic treatment market both in China and globally is continuously expanding. At the same time, numerous pharmaceutical companies are increasingly actively entering the ophthalmology treatment field. Since 2025, a large number of companies have initiated significant financing rounds aimed at accelerating clinical trials for pipelines addressing ophthalmic diseases.
 

On February 26, Super Vision Technology, Inc. announced the completion of its Series B financing. Since its establishment, the company has cumulatively raised hundreds of millions of yuan in funding, with investors including Aiboo Qing Shi, Fosun Health Capital, Longpan Investment, Chang Development Group, Yuanpei Investment, and Shuimu Ventures.
 

It is reported that Super Vision focuses on solving difficult eye diseases in humans and is committed to improving the quality of life for patients with eye diseases through innovative technologies. Currently, the company's core product under development is the Class III active i-NYS implantable ocular muscle neurostimulator, which can effectively address the challenge of congenital nystagmus. In the future, Super Vision Technology will continue to advance the development of ophthalmic medical technologies, bringing hope and light to more patients with eye diseases.
 

On February 18, Perceive Pharma announced the completion of a $15 million Series A financing round. Perceive Pharma is a spin-off from Perceive Bio, dedicated to developing novel small-molecule neuroprotective therapies, with a research focus on the treatment of glaucoma and other ophthalmic diseases.
 

The proceeds from this financing will help Perceive Pharma further advance the development of its innovative therapies, such as moving the primary therapeutic candidate PBI-671 into clinical research, bringing new hope for the treatment of ophthalmic diseases.
 

On January 20, Shenzhen Ruitong BioPharmaceutical Co., Ltd. ("Ruitong Bio") announced the completion of an angel round of financing worth tens of millions of yuan. The funds from this round will be used to advance the company’s core pipeline into clinical trials and to accelerate the technical development and pipeline expansion of the iSus® sustained-release platform.
 

According to reports, RuiTong Bio focuses on the research and development of ophthalmic new drugs and high-end medical devices, with a core focus on biodegradable long-acting sustained-release technology for the eye. It aims to address the pain point of frequent dosing associated with traditional eye drop formulations. Currently, its core platform technology, iSus®, enables single-dose sustained drug release lasting from several days to months on the ocular surface and in the posterior segment of the eye, significantly improving patient compliance and treatment outcomes.
 

January 17, iView Therapeutics announced the completion of its A++ round of financing, led by Chongqing Changsheng Shenghe Investment Fund. The proceeds will be used to advance the clinical trials and registration of the company’s R&D pipeline projects. Primarily, it will support the clinical research of IVW-1001, a first-in-class innovative chemical drug targeting dry eye disease developed by the company.
 

Currently, the IVW-1001 project has completed treatment for all patients in the Phase 1/2 clinical study for dry eye disease at 10 clinical centers in the United States. Top-line data is expected to be released in Q1 2025. After evaluating the clinical data, a meeting with the FDA will be held to determine the next pivotal clinical study.
 

On January 11, Shenzhen Ocumension successfully completed an A-round financing of over 100 million RMB. Ocumension focuses on the research and development of innovative macromolecular drugs for common fundus diseases. This round of financing will help the company accelerate the clinical progress of its multi-antibody pipeline in both China and the United States, providing a solid financial foundation for the company's further development.
 

　　Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.